BioSpace News Archive

UVision360, Inc., an innovative FemTech company, announced expansion of its intellectual property associated with its office-based, compact hysteroscopy and cystoscopy system, LUMINELLE® DTx System in the U.S.

Alliance Oncology, a division of Alliance HealthCare Services, a leading national provider of outsourced healthcare services, announced the opening of Singing River Cancer Center (SRCC). SRCC will be a part of Alliance Cancer Care, one of the largest radiation cancer networks in the southeast with over 50 years of combined experience offered at five different locations throughout Northern Alabama.

BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a leading life sciences company specializing in perinatal tissue allografts for use in regenerative therapies, today announced, in partnership with Veterans Medical Distributors Inc., a Service-Disabled Veteran-Owned Small Business (SDVOSB), that it has been awarded a five-year Federal Supply Schedule (FSS) contract for its VENDAJE™

Scientists at deCODE genetics in Iceland, a subsidiary of Amgen Inc , biopharmaceutical company headquartered in California, and their collaborators, today publish a study in The New England Journal of Medicine, that shows that antiviral antibodies against SARS-CoV2 do not decline within four months of diagnosis.

Centene Corporation (NYSE: CNC) today announced three executive leadership appointments to support the company’s continued growth

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will be presenting at the LD Micro 500 Virtual Investor conference being held virtually on September 1-4, 2020.

RLS (USA) Inc., (Radioisotope Life Sciences) has purchased General Electric’s (GE) U.S. radiopharmacy network, making it the largest pure molecular imaging focused firm in the United States.

HDT Bio Corp. is bringing immunotherapies to people around the world. With a focus on RNA, formulation, and adjuvant technologies, HDT Bio is developing biotherapeutics for oncology and infectious disease applications.

CM Life Sciences, Inc. (the “Company”) announced today that it priced its initial public offering of 38,500,000 units at $10.00 per unit.

Proceeds to support upcoming pivotal PURSUIT Trial in U.S. following recent announcement of positive results from SUI feasibility and preclinical studies